Nancy Fusco

830 total citations
21 papers, 680 citations indexed

About

Nancy Fusco is a scholar working on Reproductive Medicine, Surgery and Obstetrics and Gynecology. According to data from OpenAlex, Nancy Fusco has authored 21 papers receiving a total of 680 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Reproductive Medicine, 13 papers in Surgery and 8 papers in Obstetrics and Gynecology. Recurrent topics in Nancy Fusco's work include Ovarian cancer diagnosis and treatment (15 papers), Intraperitoneal and Appendiceal Malignancies (9 papers) and Endometrial and Cervical Cancer Treatments (8 papers). Nancy Fusco is often cited by papers focused on Ovarian cancer diagnosis and treatment (15 papers), Intraperitoneal and Appendiceal Malignancies (9 papers) and Endometrial and Cervical Cancer Treatments (8 papers). Nancy Fusco collaborates with scholars based in United States and Netherlands. Nancy Fusco's co-authors include Peter G. Rose, Michael Rodriguez, Steven Waggoner, Robert Debernardo, Charles A. Kunos, Kristine Zanotti, Ramon Adams, Kimberly Resnick, Susan Eaton and Heidi E. Frasure and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Nancy Fusco

21 papers receiving 661 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nancy Fusco United States	14	316	275	228	174	97	21	680
M. A. Bookman United States	9	316 1.0×	237 0.9×	217 1.0×	111 0.6×	102 1.1×	15	583
T. Hakes United States	11	403 1.3×	880 3.2×	318 1.4×	183 1.1×	125 1.3×	18	1.4k
Toshiyuki Sumi Japan	17	208 0.7×	200 0.7×	157 0.7×	168 1.0×	262 2.7×	81	829
W ten Bokkel Huinink Netherlands	16	553 1.8×	455 1.7×	416 1.8×	186 1.1×	331 3.4×	23	1.2k
Matthew Tan United States	7	262 0.8×	558 2.0×	335 1.5×	98 0.6×	208 2.1×	10	1.1k
Ingrid Boere Netherlands	19	210 0.7×	555 2.0×	128 0.6×	233 1.3×	186 1.9×	72	1.0k
Robert F. Asbury United States	16	107 0.3×	273 1.0×	124 0.5×	128 0.7×	96 1.0×	44	653
S. Beslija Bosnia and Herzegovina	14	149 0.5×	430 1.6×	237 1.0×	343 2.0×	92 0.9×	49	876
J Chauvergne France	16	132 0.4×	353 1.3×	219 1.0×	166 1.0×	121 1.2×	107	833
C. Tropé Norway	19	425 1.3×	215 0.8×	263 1.2×	380 2.2×	156 1.6×	44	1.0k

Countries citing papers authored by Nancy Fusco

Since Specialization

Citations

This map shows the geographic impact of Nancy Fusco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy Fusco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy Fusco more than expected).

Fields of papers citing papers by Nancy Fusco

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy Fusco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy Fusco. The network helps show where Nancy Fusco may publish in the future.

Co-authorship network of co-authors of Nancy Fusco

This figure shows the co-authorship network connecting the top 25 collaborators of Nancy Fusco. A scholar is included among the top collaborators of Nancy Fusco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy Fusco. Nancy Fusco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gruenigen, Vivian E. von, Robert M. Wenham, Heidi E. Frasure, et al.. (2014). Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. Investigational New Drugs. 32(4). 729–738. 23 indexed citations

Kunos, Charles A., Tomas Radivoyevitch, Steven Waggoner, et al.. (2013). Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers. Gynecologic Oncology. 130(1). 75–80. 74 indexed citations

Kunos, Charles A., James Brindle, Steven Waggoner, et al.. (2012). Phase II Clinical Trial of Robotic Stereotactic Body Radiosurgery for Metastatic Gynecologic Malignancies. SHILAP Revista de lepidopterología. 2. 181–181. 69 indexed citations

Gruenigen, Vivian E. von, Heidi E. Frasure, Deborah A. Smith, et al.. (2012). Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies. Anti-Cancer Drugs. 23(7). 724–730. 5 indexed citations

Rose, Peter G., Michael W. Sill, D. Scott McMeekin, et al.. (2011). A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: A gynecologic oncology group study. Gynecologic Oncology. 125(1). 158–162. 14 indexed citations

Kunos, Charles A., Steven Waggoner, Kristine Zanotti, et al.. (2011). Phase II trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical and vaginal cancer.. Journal of Clinical Oncology. 29(15_suppl). 5034–5034. 2 indexed citations

Gruenigen, Vivian von, Heidi E. Frasure, Nancy Fusco, et al.. (2010). A double‐blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin‐related hand‐foot syndrome in gynecologic oncology patients. Cancer. 116(20). 4735–4743. 43 indexed citations

Rose, Peter G., et al.. (2008). A Phase I Study of Oral Topotecan and Pegylated Liposomal Doxorubicin (Doxil) in Platinum-Resistant Ovarian and Peritoneal Cancer. American Journal of Clinical Oncology. 31(5). 476–480. 14 indexed citations

DeGeest, Koen, et al.. (2007). A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 107(2). 274–279. 30 indexed citations

10.

Rose, Peter G., Benjamin E. Greer, Ira Horowitz, Maurie Markman, & Nancy Fusco. (2006). Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: A phase I study of the Gynecologic Oncology Group. Gynecologic Oncology. 104(1). 114–119. 9 indexed citations

11.

Gruenigen, Vivian E. von, et al.. (2006). Gynecologic oncology patients' satisfaction and symptom severity during palliative chemotherapy. Health and Quality of Life Outcomes. 4(1). 84–84. 31 indexed citations

12.

Rose, Peter G., Maurie Markman, Jeffrey G. Bell, & Nancy Fusco. (2006). Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: A phase I Gynecologic Oncology Group study. Gynecologic Oncology. 102(2). 236–239. 9 indexed citations

13.

Rose, Peter G., et al.. (2004). A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma. Gynecologic Oncology. 96(2). 296–300. 30 indexed citations

14.

Rose, Peter G., et al.. (2003). Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecologic Oncology. 89(3). 429–433. 74 indexed citations

15.

Rose, Peter G., Michael Rodriguez, Joan L. Walker, et al.. (2002). A Phase I Trial of Prolonged Oral Etoposide and Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology. 85(1). 136–139. 9 indexed citations

16.

Rose, Peter G., et al.. (2002). Gemcitabine Reverses Cisplatin Resistance: Demonstration of Activity in Platinum- and Multidrug-Resistant Ovarian and Peritoneal Carcinoma. Gynecologic Oncology. 88(1). 17–21. 88 indexed citations

17.

Rose, Peter G., et al.. (2001). Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Retrospective Comparative Study of Single-Agent Dosages. Gynecologic Oncology. 82(2). 323–328. 86 indexed citations

18.

Gordon, Nahida H., et al.. (2000). A Phase II and Pharmacokinetic Study of Weekly 72-h Topotecan Infusion in Patients with Platinum-Resistant and Paclitaxel-Resistant Ovarian Carcinoma. Gynecologic Oncology. 78(2). 228–234. 36 indexed citations

19.

Rose, Peter G., et al.. (1999). Tolerance of twenty-four hour paclitaxel and carboplatin as first-line therapy in ovarian, peritoneal and fallopian tube carcinoma. International Journal of Gynecological Cancer. 9(6). 448–451. 3 indexed citations

20.

Rose, Patricia, Eric A. Jones, Ira Horowitz, et al.. (1998). Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.. Journal of Clinical Oncology. 16(5). 1849–1851. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact